A Phase I, Open Label, Multi-center, Single Dose Study to Evaluate the Pharmacokinetics of LDE225 in Healthy Subjects With Normal Hepatic Function and Subjects With Impaired Hepatic Function.
Phase of Trial: Phase I
Latest Information Update: 09 May 2019
Price : $35 *
At a glance
- Drugs Sonidegib (Primary)
- Indications Basal cell cancer; Chronic myeloid leukaemia; Pancreatic cancer; Solid tumours
- Focus Pharmacokinetics
- Sponsors Novartis; Novartis Pharma A.G.
- 18 May 2015 Status changed from recruiting to completed as reported by ClinicalTrials.gov.
- 11 Sep 2014 Planned End Date changed from 1 Jun 2014 to 1 Mar 2015 as reported by ClinicalTrials.gov.
- 01 Mar 2013 Status changed from not yet recruiting to recruiting as reported by ClinicalTrials.gov.